HCW Biologics is trading 5.1% up at $4.88 in pre-market, extending the sharp volatility seen since its 1‑for‑6 reverse stock split became effective on June 30, 2026.
- The move follows recent fluctuations as the stock adjusts to a reduced share count and restored Nasdaq bid-price compliance.
- There are no new company-specific announcements or earnings updates reported so far this morning to drive the current price action.